![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 29, 2019 2:47:23 PM
Recent ALRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 07/09/2024 12:41:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/09/2024 12:36:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/09/2024 12:30:56 PM
- Aileron Therapeutics to be Included in the Russell Microcap® Index • PR Newswire (US) • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:58:30 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:19:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 09:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:16:02 PM
- Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/15/2024 09:13:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:08:01 PM
- Aileron Therapeutics to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/06/2024 08:05:00 PM
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million • GlobeNewswire Inc. • 05/03/2024 08:05:00 PM
- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million • GlobeNewswire Inc. • 05/01/2024 12:45:03 PM
- Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) • GlobeNewswire Inc. • 05/01/2024 12:30:23 PM
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/15/2024 09:20:25 PM
- Aileron Therapeutics Announces CEO Transition • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:01:03 PM
- Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event • GlobeNewswire Inc. • 02/15/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:01:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/05/2024 06:20:21 PM
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 • GlobeNewswire Inc. • 02/01/2024 09:30:50 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/31/2024 09:05:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/29/2024 09:15:07 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM